trending Market Intelligence /marketintelligence/en/news-insights/trending/lVw8krf3H7R-fpNyYx0y7g2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Emergent BioSolutions sells anthrax vaccine to BARDA for $261M

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Emergent BioSolutions sells anthrax vaccine to BARDA for $261M

Emergent BioSolutions Inc. said the Biomedical Advanced Research and Development Authority exercised a $261 million option to purchase its AV7909 anthrax vaccine.

The option was part of the 2016 development and procurement contract, valued at up to $1.5 billion, between Emergent BioSolutions and BARDA, a division within the U.S. Department of Health and Human Services. The procured doses will be delivered to the Strategic National Stockpile, or SNS, within a 12-month period.

The contract includes a five-year base period of performance to develop the vaccine and to deliver to the SNS an initial 3 million doses, with options to procure up to an additional 50 million doses.

AV7909 is a vaccine being developed for the preventative treatment of anthrax resulting from suspected or confirmed exposure to the bacterium that causes the infection, in conjunction with the recommended course of antimicrobial therapy.

Gaithersburg, Md.-based Emergent BioSolutions is evaluating AV7909 in a late-stage trial expected to be completed in late 2020.